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ABSTRACT
Signaling lymphocytic activation molecule (SLAM;
CDw150) is a 70 kDa glycoprotein. Signaling
lymphocytic activation molecule is constitutively
expressed on memory T cells, CD56+ T cells, a subset
of T cell receptor yo+ cells, immature thymocytes and,
at low levels, on a proportion of peripheral blood
B cells. Signaling lymphocytic activation molecule is
rapidly upregulated on all T and B cells after activa-
tion. Engagement of SLAM by F(ab'h fragments of an
anti-SLAM monoclonal antibody (mAb A 12) enhances
antigen-specific T cell proliferation. In addition, mAb
A 12 was directly mitogenic for T cell clones and acti-
vated T cells. T cell proliferation induced by mAb A 12
is independent of interleukin (IL)-2, IL-4, IL-12 and
IL-15, but is cyclosporin A sensitive. Ligation of SLAM
during antigen-specific T cell proliferation resulted in
upregulation of interferon (IFN)-y production, even by
allergen-specific T helper cell (Th) 2 clones, whereas
the levels of IL-4 and IL-5 production were only
marginally affected. The mAb A 12 was unable to
induce IL-4 and IL-5 production by Th 1 clones. Co-
stimulation of skin-derived Der P 1-specific Th2 cells
from patients with atopic dermatitis via SLAM resulted
in the generation of a population of IFN-y-producing
cells, thereby reverting their phenotype to a ThO
pattern. Signaling lymphocytic activation molecule is a
high-affinity self ligand mediating homophilic cell
interaction. In addition, soluble SLAM enhances both
T and B cell proliferation. Collectively, these data indi-
cate that SLAM molecules act both as receptors and
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ligands that are not only involved in T cell expansion
but also drive the expanding T cells during immune
responses into the ThO/Th 1 pathway. This suggests
that signaling through SLAM plays a role in directing
ThO/Th 1 development.
Key words: allergy, interferon-y, signaling lymphocytic
activation molecule (CDw150), T cell activation, Th2
responses.
INTRODUCTION
T cell activation requires engagement of the T cell
receptor (TCR) by antigenic peptide/major histocom-
patibility complex (MHC) complexes expressed on the
antigen-presenting cells (APC). In addition, costimula-
tory signals mediated by an interaction between CD28
on T cells and its natural ligands CD80 and CD86
expressed on APC are required for cytokine production
and the progression of T cell proliferotion.' However,
CD28-deficient mice are still able to generate consider-
able delayed-type hypersensitivity and antiviral cytotoxic
T cell responses, indicating that CD28 is not required
for all T cell responses in vivo and that, in addition to
CD28, other molecules may have costimulatory activ-
ity.2,3 In addition to the ligand for CD40 (CD40 L),4
these molecules may include novel T cell surface mole-
cules that are induced or upregulated early after T cell
activation. Here we show that signaling lymphocytic
activation molecule is one of the early activation mole-
cules on T cells." Engagement of SLAM by an anti-SLAM
monoclonal antibody (mAb) results in the expansion of
activated T cells and interferon (IFN)-y production. In
the present communication, the structure and functions
of SLAM, particularly its capacity to redirect allergen-
specific Th2 responses into a ThO-like pathway, will be
discussed.
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SIGNALING LYMPHOCYTIC ACTIVATION
MOLECULE STRUCTURE
Signaling lymphocytic activation molecule is a heavily
glycosylated 70 kDa type 1 transmembrane protein com-
posed of a 202 amino acid (aa) extracellular region, a
22 aa transmembrane domain and a 77 aa cytoplasmic
tail. The extracellular region of SLAM contains six cysteine
residues that are involved in the disulfide bond formation
of the two immunoglobulin (Ig) loops characteristic for
the Ig superfamily structure and comprises one constant
and one variable region domain.
Signaling lymphocytic activation molecule has a low
degree of homology with other Ig supergene family
members, such as human Ly 9, CD48 (26%), CD58
(17%), and with the mouse natural killer (NK) cell signaling
molecule 2B4 (28%).5 Signaling lymphocytic activation
molecule also has homology with three putative mem-
brane receptors of the Molluscus Contagious Virus (MCV),
which is a tumorigenic poxvvirus." The gene encoding
human SLAM has been localized on the long arm of
chromosome 1 in the region of 1q21 .2-1 q23 (B Cocks
et 01., unpubl. obs., 1997). This region contains many
genes important in cell-cell interactions, leukocyte adhe-
sion and trafficking, including CD48, Ly9, selectins and
myelin PO. The cytoplasmic tail of SLAM contains four
potential tyrosine phosphorylation sites, three of which
conform to the consensus sequences reported to bind one
class of SH2 dorncins.?
Four alternatively spliced isoforms of human SLAM
have been identified. These include a truncated trans-
membrane form, a secreted form derived by an in-frame
deletion of 90 b.p., with the deleted aa encompassing
the entire transmembrane region, and an isoform that
lacks the leader sequence and that, consequently, is
expressed introcytoplosmiccllv." All SLAM isoforms are
present in peripheral blood lymphocytes, CD4 + T cell
clones, B cells, Epstein-Barr virus (EBV)-transformed
B cell lines and fetal thymocytes. The existence of different
alternatively spliced isoforms suggests that these may
have different functions in different lymphoid populations
and during differentiation of these cells.
SIGNALING LYMPHOCYTIC ACTIVATION
MOLECULE EXPRESSION
Signaling lymphocytic activation molecule is primarily
expressed on lymphoid cells. Signaling lymphocytic acti-
vation molecule is constitutively expressed on immature
thymocytes, a proportion of CD8+ and CD4 + T cells
within the CD45 RO+ memory T cell population, some
TCR yo+ T cells, a proportion of B cells, CD56+ T cells,
T cell clones and EBV-transformed B cell lines. Signaling
lymphocytic activation molecule receptors are not present
on NK cells, monocytes and granulocytes, most human
malignant T cell lines and myeloid cell lines. However,
SLAM is rapidly (within 2 h) induced on all CD45 RA+
ncfve T cells and B cells following activation, indicating
that SLAM receptors may playa role in the early stages of
T and B cell octivotion."
ENGAGEMENT OF SLAM RECEPTORS RESULTS IN
T CELL EXPANSION
The anti-SLAM mAb A 12 used as a surrogate ligand
enhances antigen-specific T cell proliferation. In addition,
mAb A 12 directly induces proliferation of T cell clones,
phytohemagglutinin (PHA)-blasts, or T cells that had been
activated by specific antigens. Single Fab or F(ab'b frag-
ments of mAb A 12 were also effective, indicating that
cross-linking of SLAM receptors was not required for the
induction of T cell proliferation. The direct proliferation-
inducing effects of SLAM were dependent on the 'activation
state' of the T cells, as the effect decreased in time following
activation of the T cells and T cell clones despite the levels
of SLAM expression on the surface of these cells remaining
unaltered." These results suggest that stimulation via SLAM
requires an activation-induced modification of this mole-
cule or association of SLAM with other activation-induced
signaling components.
T cell proliferation induced through stimulation of
SLAM-receptors is interleukin (IL)-2, IL-4, IL-12 and IL-15
independent but is cyclosporin A sensitive, indicating
that, despite IL-2 not being required, calcineurin and
nuclear factor of activated T cell (NFAT) family members
seem to be involved in SLAM-mediated siqnolinq."
SIGNALING LYMPHOCYTIC ACTIVATION
MOLECULE IS A HIGH-AFFINITY SELF LIGAND
Determination of the ligand for SLAM using a SLAM-Ig
fusion protein identified SLAM as a self ligand. The fluor-
escent-labeled SLAM-Ig fusion protein bound only
to cells expressing SLAM, including SLAM-transfected
L cells. This hornophi!ic interaction between SLAM mole-
cules was confirmed by measuring plasmon resonance.
Both the recombinant soluble forms of the extracellular
domain of SLAM and the naturally occurring soluble form
of SLAM (in which only the transmembrane region is
deleted) showed strong homophilic interactions with an
affinity of approximately 0.1 nrnol/L. These high affinity
SLAM-SLAM interactions had functional consequences,
as BAF-3 cells transfected with SLAM molecules immedi-
ately form cell aggregates whereas the wild-type cells
grow in single cell suspension (B Cocks et a/., unpubl.
obs., 1997). Similar results were observed with EL-4 cells,
whereas EL-4 cells transfected with chimeric SLAM mole-
cules consisting of the extracellular domain of CD8 and
the cytoplasmic domain of SLAM failed to induce adhe-
sions of EL-4 cells. Collectively, these results indicate that
homophilic SLAM interactions play an important role in
inducing cell adhesion. Furthermore, the soluble recom-
binant forms of SLAM induce, in a dose-dependent
fashion, proliferation of pre-activated B cells9 and (to a
lesser extent) of CD4 + T cell clones (B Cocks et a/.,
unpubl. obs., 1997).
The identification of SLAM as a self ligand is not unex-
pected, as other molecules that share sequence homology
with SLAM interact similarly. Human Ly 9 and myelin PO,
which are mapped on the same chromosomal region as
SLAM, and other Ig-supergene family members, such as
CD31 and CD56, interact in a homophilic fashion.
The observation that many other members of the
Ig-supergene family (such as CD28 and CD80), CD28,
CD86, CD2, CD58, TCR and MHC interact in a hetero-
philic fashion suggests an evolution of Ig-supergene
family members by gene duplication from homophilically
interacting precursors.!?
SIGNALING LYMPHOCYTIC ACTIVATION
MOLECULE ENGAGEMENT INDUCES IFN-y
PRODUCTION AND REDIRECTS Th2 RESPONSES
T lymphocytes are important producers of cytokines and
different CD4 + helper subsets have been identified based
on their cytokine production profile. T helper 1 cells
produce, among other cytokines, IL-2, IFN-yand lvrnpho-
toxin but not IL-4 and IL-5, whereas Th2 cells produce
IL-4, IL-5 and IL-13 but not (or only very low levels of)
IFN-y. Both T cell subsets produce IL-3, granulocyte-
macrophage colony stimulating factor (GM-CSF) and
tumor necrosis factor (TNF)-a. A third subset, the ThO
cells, produces both Th1 and Th2 cytokines. The differ-
ences in cytokine production patterns of the various Th cell
subsets are also reflected in their functions. Th1 cells are
generally involved in cellular immune responses, such
as delayed-type hypersensitivity reactions and monocyte
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activation, whereas Th2 cells predominantly provide help
for B cells in antibody production.!' It is well documented
that allergen-specific T cells derived from atopic patients
generally belong to the Th2 subset.12- 14 Interleukin-4 and
IL-13 produced by these cells following activation induce
IgE synthesis by B cells, whereas IFN-y produced by Th1
and ThO cells inhibits IL-4- and IL-13-driven IgE synthe-
siS. 1S, 16 Interestingly, engagement of SLAM during
antigen-specific T cell responses strongly enhances IFN-y
production, even by allergen-specific Th2 clones.
In contrast, costimulation through SLAM failed to
induce IL-4 or IL-5 production by Th1 clones and only
marginally affected the production of these cytokines by
ThO and Th2 clones.s Thus, SLAM engagement directs
T cell responses towards a Th1 pathway. This notion was
confirmed by the observation that the responses of Der
p I-specific Th2 cells obtained from skin biopsies of
patients with atopic dermatitis following a local challenge
with Der P 1 could be redirected to a ThO response.'?
Engagement of SLAM during allergen-specific stimula-
tion of these Th2 cell populations resulted in the generation
of a stable population of IFN-y-producing Th1 and ThO
clones. In addition, the production of IL-4 and, particularly,
IL-13 was downregulated in these cultures. This had impor-
tant biological consequences, in that supernatants
obtained from the Der p I-specific T cell population cul-
tured in the presence of anti-SLAM F(ab'b fragments, in
contrast with their control counterparts, failed to induce IgE
synthesis by B cells activated by anti-CD40 mAb. 17 The
capacity to induce IgE synthesis could be partly restored by
neutralizing anti-IFN-y mAb, indicating that the quantities
of IFN-y produced following ligation of SLAM are sufficient
to completely counteract the IgE production-inducing
activity of the remaining IL-4 and IL-13 in these super-
natants. In addition, these results indicate that the SLAM-
signaling pathway may provide a novel way to intervene in
Th2 cell-mediated allergic diseases.
SIGNALING LYMPHOCYTIC ACTIVATION
MOLECULE SIGNALING
Stimulation of EL-4 (mouse thymoma) or Jurkat (human
T leukemia) cells transfected with SLAM via the TCR
resulted in a strong reduction in the phosphorylation of
many tyrosine kinases. In contrast, no effects on tyrosine
kinase activity were observed in EL-4 or Jurkat cells that
were transfected wit~ chimeric SLAM molecules consist-
ing of the extracellular part of CD8 and the cytoplasmic
portion of SLAM. This is consistent with the notion that
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SLAM, in contrast with CD8, is a high-affinity self ligand.
Preliminary studies revealed that, among others, the
phosphorylation of ZAP 70 and cbl was strongly inhibited
by SLAM. The same was observed for CD3E.
The strong reduction in tyrosine kinase activation fol-
lowing SLAM-SLAM interactions of EL-4 and Jurkat cells
could be partially restored by pervanadate, suggesting
that tyrosine phosphatases, probably recruited by SLAM,
play an important role in downregulating phospho-
tyrosine kinase activation (C Terhorst et 01., unpubl. obs.,
1997). These data suggest that cell-bound SLAM-SLAM
interactions confer a negative signal to activated T cells,
which is relieved by anti-SLAM mAb and probably, but to
a lesser extent, by monomeric soluble SLAM molecules.
CONCLUDING REMARKS
The present information indicates that SLAM plays a role
in Th cell expansion following antigen-specific activa-
tion. In contrast to CD28, SLAM does not seem to be
involved in the initiation of T cell activation, but once
T cells are activated, engagement of SLAM results in a
direct, IL-2- and IL-4-independent proliferation of these
cells. Together with its capacity to induce preferentially
IFN-y production, these observations indicate that liga-
tion of SLAM receptors directs the expanding T cells into
the Th 1 pathway, suggesting that SLAM may play a
general role in Th1 cell differentiation.
Signaling through SLAM can even reverse allergen-
specific Th2 cell responses, as it resulted in the
generation of a stable population of IFN-y-producing
Th1 cells, thereby redirecting the allergen-specific Th2
responses into the ThO/Th 1 pathway. Whether this induc-
tion of IFN-y production by Th2 cell populations indeed
reflects induction of IFN-y production by IL-4-producing
allergen-specific Th2 cells or differentiation of IFN-y-
producing Th1 cells from non-IL-4-producing T cells
present in these skin-derived T cell populations remains
to be determined. However, these results suggest that
modulation of the SLAM signaling pathway may provide
a novel way to intervene in allergic diseases. Although the
SLAM signaling pathway remains to be elucidated, pre-
liminary findings suggest that SLAM-SLAM interactions
between cell-bound forms of SLAM may confer a 'nega-
tive signal', as judged by a general inhibition of tyrosine
kinase phosphorylation following TCR activation. This
notion is consistent with the observation that all anti-
SLAM-mAb generated thus far (n = 20) have 'agonistic'
activity, which probably should be interpreted as reflect-
ing neutralization of inhibitory signals mediated by cell-
bound SLAM-SLAM interactions. Because soluble SLAM
also enhances T cell proliferation, it can be concluded
that it probably has similar effects. Release of these nega-
tive signals (probably mediated by tyrosine phosphatases)
results in T cell expansion and IFN-y production by
these cells. Characterization of the various components
involved in the SLAM signaling pathway will give a better
insight into the mechanisms underlying this novel 'nega-
tive' signaling pathway in T cells, which playa role in
T cell expansion and IFN-y production by these cells.
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